Atara Biotherapeutics (NASDAQ:ATRA) Upgraded at TD Cowen

TD Cowen upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) to a strong-buy rating in a research report report published on Friday morning,Zacks.com reports.

Several other brokerages have also weighed in on ATRA. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their target price for the stock from $25.00 to $18.00 in a research note on Friday, August 16th. Finally, Canaccord Genuity Group upped their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.67.

Atara Biotherapeutics Price Performance

ATRA opened at $12.18 on Friday. Atara Biotherapeutics has a twelve month low of $6.50 and a twelve month high of $39.50. The company’s 50-day moving average price is $9.63 and its two-hundred day moving average price is $9.98. The stock has a market cap of $70.16 million, a price-to-earnings ratio of -0.47 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the previous year, the company posted ($16.50) EPS. As a group, sell-side analysts anticipate that Atara Biotherapeutics will post -9.42 earnings per share for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after buying an additional 4,043 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Atara Biotherapeutics during the 2nd quarter valued at about $53,000. FMR LLC boosted its position in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the last quarter. State Street Corp grew its holdings in shares of Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics in the second quarter worth approximately $79,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.